Martin Reck

Jun 17, 2024 | onclive.com | Martin Reck

Five-Year Outcomes With First-Line (1L) Nivolumab + Ipilimumab + Chemotherapy (N + I + C) vs C in Patients (pts) With Metastatic NSCLC (mNSCLC) in CheckMate 9LADr. Martin Reck presents the five year update of CheckMate 9LA (NCT03215706) and exploratory analysis of efficacy in patients who discontinued treatment due to treatment related adverse events in patients with metastatic non-small lung cancer.

Apr 26, 2024 | ascopubs.org | Martin Reck

This overview offers a comprehensive review of current first-line treatment opportunities together with the corresponding major trial results. We discuss pertinent queries from routine clinical practice, such as the best approach for PD-L1 high expressers, the significance of dual checkpoint blockade, and discontinuation strategies in long-term responders.

Sep 10, 2023 | ascopubs.org | Helena A. Yu |James Yang |Martin Reck |Luis Paz-Ares

After tumor progression with EGFR TKI therapy and PBC in patients with EGFR -mutated NSCLC, HER3-DXd once every 3 weeks demonstrated clinically meaningful efficacy with durable responses, including in CNS metastases. A phase III trial in EGFR- mutated NSCLC after progression on an EGFR TKI is ongoing (HERTHENA-Lung02; ClinicalTrials.gov identifier: NCT05338970 ).

Sep 10, 2023 | brnw.ch | Helena A. Yu |James Yang |Martin Reck |Luis Paz-Ares

For patients with epidermal growth factor receptor (EGFR)–mutated advanced non–small-cell lung cancer (NSCLC), initial treatment typically includes one or two EGFR tyrosine kinase inhibitor (TKI) regimens comprising either a third-generation EGFR TKI or a first- or second-generation EGFR TKI followed by a third-generation EGFR TKI when the EGFR T790M mutation is detected.1 After disease progression on EGFR TKI therapy, patients are usually treated with platinum-based chemotherapy (PBC; with...